8-K 1 d660091d8k.htm 8-K 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 7, 2019

 

 

Calithera Biosciences, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-36644   27-2366329

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

343 Oyster Point Blvd., Suite 200

South San Francisco, California

  94080
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (650) 870-1000

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications  pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company  ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

 

 

 


Item 2.02.

Results of Operations and Financial Condition.

On January 7, 2019, Calithera Biosciences, Inc. issued a press release titled “Calithera Biosciences Provides Corporate Updates and Announces Key Executive Promotions to Drive Continued Growth of the Company’s Pipeline ” a copy of which is filed as Exhibit 99.1 hereto. In the press release, we announced that based upon preliminary estimates, our cash, cash equivalents and investments totaled $136.2 million at December 31, 2018 and we expect to utilize cash and investments between $75 and $85 million in 2019.

 

Item 8.01.

Other Events.

The information contained in Item 2.02 above and the press release, dated January 7, 2019, titled “Calithera Biosciences Provides Corporate Updates and Announces Key Executive Promotions to Drive Continued Growth of the Company’s Pipeline” are incorporated herein by reference.

 

Item 9.01.

Financial Statements and Exhibits.

(d)    Exhibits.

 

Exhibit

  

Description

99.1    Press Release, dated January  7, 2019, titled “Calithera Biosciences Provides Corporate Updates and Announces Key Executive Promotions to Drive Continued Growth of the Company’s Pipeline”.


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    Calithera Biosciences, Inc.
Dated: January 7, 2019     By:  

/s/ Susan M. Molineaux, Ph.D.

      Susan M. Molineaux, Ph.D.
      President and Chief Executive Officer